Effects of racial/ethnic disparities in healthcare utilization on antibiotic use, 2016/2018

Scott W. Olesen, PhD[1*], Sanjat Kanjilal, MD MPH[2], Stephen M. Kissler, PhD[1], Daphne S. Sun, BS[1], Yonatan H. Grad, MD PhD[1*]

1 Department of Immunology and Infectious Diseases, Harvard Chan School of Public Health, Boston, MA
2 Department of Population Medicine, Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, MA

* Correspondence:
Harvard Chan School of Public Health
665 Huntington Ave
Building 1 Room 715
Boston, MA 02115
732.351.2311
olesen@hsph.harvard.edu

Word count: 1402

Keywords: antibiotics, race/ethnicity, equity, healthcare utilization

ABSTRACT

White Americans make more office-based and emergency department visits per capita than other races/ethnicities, but the proportion of visits during which antibiotics are administered or prescribed is similar across races/ethnicities. Racial/ethnic disparities in antibiotic use may be due more to disparities in healthcare access and utilization than to prescriber behavior.

INTRODUCTION

Antibiotics are an important therapy for treating infectious disease, but use of antibiotics carries risk of negative effects, like adverse events or antibiotic resistance. Avoiding antibiotic overuse through antibiotic stewardship helps avoid unnecessary and inappropriate antibiotic use. However, underuse of antibiotics, when a person has an infection for which antibiotics are medically recommended but the person does not receive the antibiotic, is also problematic [1]. Even for conditions like sore throat or otitis media, which typically resolve without complications, failure to use antibiotics can sometimes lead to substantial morbidity [2].

Disparities in antibiotic use rates, when one population uses more or less antibiotics than another group, are a likely indicator of antibiotic overuse or underuse [1,3]. Many studies have shown that prescribing practice varies by patient race/ethnicity, usually with whites more likely to receive antibiotics or broader-spectrum antibiotics [1,4–7].

However, studies of antibiotic prescribing per healthcare visit, while important, do not address all the factors that could lead to disparities in antibiotic use. First, rates of bacterial infections may vary between populations. Second, access to healthcare and healthcare seeking behavior may differ across populations. In other words, the probability that someone with an infection presents at a healthcare visit may vary by population. Third, different populations may be more or less likely to receive antibiotics when they present at a healthcare visit. Studies of prescribing

per visit only address the third step, but previous work suggests that geographical differences in antibiotic use rates are due more to differences in healthcare access and utilization than to prescribing practice [8] and that temporal trends in racial disparities in antibiotic use among children are due more to changes in healthcare utilization than to changes in prescribing practice [7].

Here, we use a nationally representative survey of healthcare visits to assess the relative importance of healthcare utilization and prescribing practice on antibiotic use by race/ethnicity. We hypothesized that any racial/ethnic differences in antibiotic use are due both to differences in healthcare utilization, measured as per capita rates of ambulatory care visits, as well as to differences in prescribing practice, measured as the probability that an antibiotic will be used given that certain diagnoses are present.

METHODS

We analyzed data from the National Ambulatory Medical Care Survey (NAMCS) and National Hospital Ambulatory Medical Care Survey (NHAMCS), two nationally representative samples used to characterize antibiotic prescribing practice [9,10]. Each survey is a sample of office-based and emergency department visits with associated patient demographics, diagnosis codes, and prescriptions as provided by physicians or hospital staff. Missing race/ethnicity data are imputed using a model developed by NAMCS/NHAMCS staff [10]. We used the two most recent years with data from both surveys, 2016 and 2018. NHAMCS from 2017 data were not available [11].

Each healthcare visit was classified as antibiotic-appropriate, potentially antibiotic-appropriate, or antibiotic-inappropriate by a two-step process [12]. First, using previously established categorizations of the ICD-10 diagnosis codes, each diagnosis code associated with each visit

was classified as always antibiotic-appropriate, sometimes antibiotic-appropriate, or never antibiotic-appropriate. Second, each visit was classified based on its diagnoses. A visit with at least one always-appropriate diagnosis was classified as antibiotic-appropriate. Remaining unclassified visits with at least one sometimes-appropriate code were classified as potentially antibiotic-appropriate. Remaining unclassified visits with at least one never-appropriate code were classified as antibiotic-inappropriate. The remaining visits were left unclassified. Note that, in this classification, most visits are considered antibiotic-inappropriate, not because patients are seeking antibiotics for antibiotic-inappropriate conditions, but rather because most healthcare visits are not made for the purpose of treating bacterial infections.

Separately, each visit was classified as a visit with antibiotics if any of the prescribed or administered medications included oral antibiotics [9].

Differences in rates were assessed using *t*-tests, with $p < 0.01$ considered statistically significant, as recommended in the NHAMCS documentation [10]. Differences in proportions were assessed using χ^2 tests. All analyses were performed using R (version 4.0.5), with the *survey* package (version 4.0) used to account for the complex survey design in variance estimation. The population denominators for each race/ethnicity provided in the NAMCS/NHAMCS documentation, which are drawn from US Census estimates, were used for population-based rate estimates. Code to reproduce these analyses is available at GitHub (doi: 10.5281/zenodo.6233588).

RESULTS

During 2016 and 2018, rates of physician office and hospital emergency room visits varied by race/ethnicity. Non-Hispanic whites made the highest rate of visits, 7.0 (95% CI 6.6 to 7.4) annual visits per capita, followed by non-Hispanic Blacks (5.5, 95% CI 4.9 to 6.0), Hispanics

100 (5.5, 95% CI 4.7 to 6.3), and non-Hispanic people of multiple or other races (4.2, 95% CI 3.2 to
101 5.2; Figure 1a). The difference in rates of visits was mostly attributable to different rates of
102 antibiotic-inappropriate visits, that is, visits with no associated diagnoses for which antibiotics
103 were appropriate or sometimes appropriate (*t*-tests, Figure 1a).
104
105 The proportion of visits during which antibiotics were prescribed or administered (5.5%, 95% CI
106 4.9% to 6.0%) did not vary statistically significantly by race/ethnicity ($p = 0.57$, χ^2 test), even
107 when stratifying by the antibiotic-appropriateness of the diagnoses associated with the visit ($p >$
108 0.05, χ^2 tests; Figure 1b).
109
110 Non-Hispanics whites had a higher rate of visits with antibiotics administered or prescribed (0.40
111 annual visits per capita, 95% CI 0.34 to 0.46) compared to non-Hispanic people of multiple or
112 other races (0.20 annual visits per capita, 95% CI 0.14 to 0.27; $p < 0.001$, *t*-test), but differences
113 between whites and Blacks (who had 0.33 annual antibiotic visits per capita, 95% CI 0.27 to
114 0.39) and between whites and Hispanics (who had 0.29, 95% CI 0.23 to 0.36) were not
115 statistically significant ($p > 0.01$, *t*-tests).
116
117 **DISCUSSION**
118 In this analysis of nationally representative survey data, whites made more healthcare visits per
119 capita. However, there was no statistically significant difference across races/ethnicities in the
120 proportion of visits that included antibiotics, even when stratifying by whether antibiotics were
121 appropriate for the visit. These results suggest that differences in healthcare utilization are at
122 least as important as per-visit prescribing practice to disparities in antibiotic use. For example,
123 whites had a 27% higher rate of healthcare visits than Blacks (7.0 vs. 5.5 annual visits per
124 capita), but the point estimate in the proportion of visits with antibiotics was 6% lower for whites
125 (5.7% vs. 6.0% of visits with antibiotics prescribed). Thus, difference in the overall rate of

126 antibiotic use between whites and Blacks is likely more attributable to differences in the number
127 of opportunities for antibiotics to be prescribed rather than to the probability that an antibiotic will
128 be prescribed at a visit.
129
130 This study's primary strength is its use of a nationally representative survey. Its most important
131 limitation is that the survey's sampling frame is the healthcare visits. A survey of visits can
132 estimate visits by race/ethnicity and the proportions of visits with antibiotics, but it cannot
133 address the proportion of infections that are treated with antibiotics because not every infection
134 that merits antibiotics results in a visit. Thus, without knowing the underlying rates of disease,
135 we cannot determine whether patients of different races/ethnicities with antibiotic-treatable
136 infections are more or less likely to present for treatment [1]. For example, if non-whites had
137 higher underlying rates of bacterial infections, then whites' approximately equal rates of
138 antibiotic-appropriate visits actually represent a disparity in healthcare access or healthcare
139 seeking.
140
141 This study has other important limitations. First, these national surveys did not have sufficient
142 statistical power to characterize any differences across races/ethnicities in the probability of per-
143 visit antibiotic use. For example, the point estimate for the proportion of Blacks' antibiotic-
144 appropriate visits that had antibiotics (35%, 95% CI 27% to 43%) was higher than that for whites
145 (30%, 95% CI 25% to 35%), but the confidence intervals were wide and overlapping (Figure 1b).
146 Second, these surveys do not include every kind of visit type and exclude, notably, urgent care,
147 telephone or telehealth contact, hospital outpatient departments, Veterans Administration
148 hospitals, and inpatient care. People of different races/ethnicities seek care in different
149 healthcare contexts [7] and so these results are necessarily incomplete. Third, there may be
150 systematic biases in the diagnosis codes that prescribers assign to people of different races

with the same underlying disease [1]. Finally, the available data cannot assess the effect of the Covid-19 pandemic on antibiotic prescribing patterns.

Despite these limitations, these results point to two important components for ensuring equity in the quality of care for bacterial infections: first, characterizing racial/ethnic differences in underlying rates of antibiotic-treatable infections, and second, mitigating barriers to healthcare access and utilization. It may be that these components are more important to antibiotic equity than prescriber behavior.

STATEMENTS

Conflicts of interest

SWO is an employee of Biobot Analytics, Inc. YHG has consulted for GSK, holds grants from Pfizer and Merck, and serves on the scientific advisory board for Day Zero Diagnostics.

Funding

YHG: Wellcome Trust Award 219812/Z/19/Z and internal Harvard T. H. Chan School award.

Data availability

Source data are openly available from the National Center for Health Statistics (https://ftp.cdc.gov/pub/Health_Statistics/NCHS/Datasets, https://www.cdc.gov/nchs).

172 **Figure 1.** (a) Annual office-based and emergency department visits per capita, stratified by
173 patient race/ethnicity and by antibiotic-appropriateness of the diagnoses recorded for the visit.
174 Error bars show 95% confidence intervals. *: *t*-test, $p < 0.01$. (b) Proportion of visits with
175 antibiotics administered or prescribed.



177

178 **REFERENCES**

179 1. Fleming-Dutra KE, Shapiro DJ, Hicks LA, Gerber JS, Hersh AL. Race, Otitis Media, and
180 Antibiotic Selection. Pediatrics **2014**; 134:1059–1066.

181 2. Little P. Delayed prescribing of antibiotics for upper respiratory tract infection. BMJ **2005**;
182 331:301.

183 3. Cosgrove SE, Klein EY. Reassessing the Link Between Healthcare Access and Outpatient
184 Antibiotic Prescribing. J Infect Dis **2021**; 223:2017–2019.

185 4. Olesen SW, Grad YH. Racial/Ethnic Disparities in Antimicrobial Drug Use, United States,
186 2014–2015 - Volume 24, Number 11—November 2018 - Emerging Infectious Diseases
187 journal - CDC. Emerg Infect Dis **2018**; 24:2126–2128.

188 5. Goyal MK, Johnson TJ, Chamberlain JM, et al. Racial and Ethnic Differences in Antibiotic
189 Use for Viral Illness in Emergency Departments. Pediatrics **2017**; :e20170203.

190 6. Steinman MA, Landefeld SC, Gonzales R. Predictors of Broad-Spectrum Antibiotic
191 Prescribing for Acute Respiratory Tract Infections in Adult Primary Care. JAMA **2003**;
192 289:719–725.

193 7. Halasa NB, Griffin MR, Zhu Y, Edwards KM. Differences in antibiotic prescribing patterns for
194 children younger than five years in the three major outpatient settings. J Pediatr **2004**;
195 144:200–205.

196 8. Kissler SM, Klevens RM, Barnett ML, Grad YH. Childhood respiratory outpatient visits
197 correlate with socioeconomic status and drive geographic patterns in antibiotic prescribing. J
198 Infect Dis **2021**;

199 9. Fleming-Dutra KE, Hersh AL, Shapiro DJ, et al. Prevalence of Inappropriate Antibiotic
200 Prescriptions Among US Ambulatory Care Visits, 2010-2011. JAMA **2016**; 315:1864–1873.

201 10. Centers for Disease Control and Prevention. Ambulatory Health Care Data Datasets and
202 Documentation. 2021; Available at:
203 https://www.cdc.gov/nchs/ahcd/datasets_documentation_related.htm. Accessed 13
204 February 2022.

205 11. Centers for Disease Control and Prevention. Notices for NAMCS and NHAMCS Public Use
206 Data File Users. 2021; Available at: https://www.cdc.gov/nchs/ahcd/notice.htm. Accessed
207 12 February 2021.

208 12. Chua K-P, Fischer MA, Linder JA. Appropriateness of outpatient antibiotic prescribing
209 among privately insured US patients: ICD-10-CM based cross sectional study. BMJ **2018**;
210 364:k5092.

211